Inhaled nitric oxide reduces pulmonary artery pressures in portopulmonary hypertension

J. Y. Findlay, B. A. Harrison, D. J. Plevak, Michael Joseph Krowka

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Pulmonary artery hypertension in association with liver failure (portopulmonary hypertension [PPHTN]) is a significant barrier to liver transplantation because patients with this condition have a very high mortality when transplantation is undertaken. Inhaled nitric oxide (NO), a potent pulmonary vasodilator, reduces pulmonary artery pressure (PAP) in some patients with primary pulmonary hypertension, but its effect in patients with PPHTN is controversial. We investigated the hemodynamic effects of inhaled NO in 6 patients with PPHTN. Five of 6 patients responded to NO inhalation with decreases in PAP and pulmonary vascular resistance of greater than 10%; these decreases were statistically significant at NO concentrations of 10 and 30 ppm. Cardiac output did not significantly change. We conclude that inhalation of NO reduces PAPs in some patients with PPHTN.

Original languageEnglish (US)
Pages (from-to)381-387
Number of pages7
JournalLiver Transplantation and Surgery
Volume5
Issue number5
StatePublished - 1999

Fingerprint

Pulmonary Artery
Nitric Oxide
Hypertension
Pressure
Inhalation
Liver Failure
Vasodilator Agents
Pulmonary Hypertension
Cardiac Output
Vascular Resistance
Liver Transplantation
Transplantation
Hemodynamics
Lung
Mortality

ASJC Scopus subject areas

  • Hepatology
  • Surgery

Cite this

Inhaled nitric oxide reduces pulmonary artery pressures in portopulmonary hypertension. / Findlay, J. Y.; Harrison, B. A.; Plevak, D. J.; Krowka, Michael Joseph.

In: Liver Transplantation and Surgery, Vol. 5, No. 5, 1999, p. 381-387.

Research output: Contribution to journalArticle

@article{5b150ddae2cd44eca9c51e7324448769,
title = "Inhaled nitric oxide reduces pulmonary artery pressures in portopulmonary hypertension",
abstract = "Pulmonary artery hypertension in association with liver failure (portopulmonary hypertension [PPHTN]) is a significant barrier to liver transplantation because patients with this condition have a very high mortality when transplantation is undertaken. Inhaled nitric oxide (NO), a potent pulmonary vasodilator, reduces pulmonary artery pressure (PAP) in some patients with primary pulmonary hypertension, but its effect in patients with PPHTN is controversial. We investigated the hemodynamic effects of inhaled NO in 6 patients with PPHTN. Five of 6 patients responded to NO inhalation with decreases in PAP and pulmonary vascular resistance of greater than 10{\%}; these decreases were statistically significant at NO concentrations of 10 and 30 ppm. Cardiac output did not significantly change. We conclude that inhalation of NO reduces PAPs in some patients with PPHTN.",
author = "Findlay, {J. Y.} and Harrison, {B. A.} and Plevak, {D. J.} and Krowka, {Michael Joseph}",
year = "1999",
language = "English (US)",
volume = "5",
pages = "381--387",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Inhaled nitric oxide reduces pulmonary artery pressures in portopulmonary hypertension

AU - Findlay, J. Y.

AU - Harrison, B. A.

AU - Plevak, D. J.

AU - Krowka, Michael Joseph

PY - 1999

Y1 - 1999

N2 - Pulmonary artery hypertension in association with liver failure (portopulmonary hypertension [PPHTN]) is a significant barrier to liver transplantation because patients with this condition have a very high mortality when transplantation is undertaken. Inhaled nitric oxide (NO), a potent pulmonary vasodilator, reduces pulmonary artery pressure (PAP) in some patients with primary pulmonary hypertension, but its effect in patients with PPHTN is controversial. We investigated the hemodynamic effects of inhaled NO in 6 patients with PPHTN. Five of 6 patients responded to NO inhalation with decreases in PAP and pulmonary vascular resistance of greater than 10%; these decreases were statistically significant at NO concentrations of 10 and 30 ppm. Cardiac output did not significantly change. We conclude that inhalation of NO reduces PAPs in some patients with PPHTN.

AB - Pulmonary artery hypertension in association with liver failure (portopulmonary hypertension [PPHTN]) is a significant barrier to liver transplantation because patients with this condition have a very high mortality when transplantation is undertaken. Inhaled nitric oxide (NO), a potent pulmonary vasodilator, reduces pulmonary artery pressure (PAP) in some patients with primary pulmonary hypertension, but its effect in patients with PPHTN is controversial. We investigated the hemodynamic effects of inhaled NO in 6 patients with PPHTN. Five of 6 patients responded to NO inhalation with decreases in PAP and pulmonary vascular resistance of greater than 10%; these decreases were statistically significant at NO concentrations of 10 and 30 ppm. Cardiac output did not significantly change. We conclude that inhalation of NO reduces PAPs in some patients with PPHTN.

UR - http://www.scopus.com/inward/record.url?scp=0032882581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032882581&partnerID=8YFLogxK

M3 - Article

C2 - 10477839

AN - SCOPUS:0032882581

VL - 5

SP - 381

EP - 387

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 5

ER -